CAS:186692-46-6

(Synonyms CYC202; R-roscovitine; Seliciclib)

186692-46-6 Technical Data:

Price and Availability of Cas No:186692-46-6

Cas : 186692-46-6 M.Wt: 354.4493
Cas : 186692-46-6 Formula: C19H26N6O
Cas : 186692-46-6 Purity: >98 %
Cas : 186692-46-6 Storage: at 20℃ 2 years
Cas : 186692-46-6 Solubility: 10 mM in DMSO
Cas : 186692-46-6 Name: Roscovitine

USD
1g/$920	In-stock
10mg/$60	In-stock
50mg/$150	In-stock
100mg/$200	In-stock
200mg/$280	In-stock
500mg/$590	In-stock
1g	Get quote
5g	Get quote
>10g	Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please inquire via sales@chemexpress.cn or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Online Inquiry

Inquiry Online

Hide

Salutation:		Country:
Customer:		Company Name:
Email:		Requested quantity:
Remarks:

186692-46-6 Data Sheet:

Introduction of 186692-46-6 :
Roscovitine is a potent and selective CDK inhibitor with IC₅₀ of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively. IC50 & Target: IC50: 0.2 μM (CDK5), 0.65 μM (Cdc2), 0.7 μM (CDK2)^[1] In Vitro: Roscovitine displays high efficiency and high selectivity towards some cyclin-dependent kinases. The kinase specificity of Roscovitine is investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl). Most kinases are not significantly inhibited by Roscovitine. Cdc2, Cdk2, and Cdk5 only are substantially inhibited (IC₅₀ values of 0.65, 0.7, and 0.2 μM, respectively). Cdk4k and Cdk6 are very poorly inhibited by Roscovitine (IC₅₀>100 μM). Extracellular regulated kinases erk1 and erk2 are inhibited with an IC₅₀ of 34 μM and 14 μM, respectively. Roscovitine inhibits the proliferation of mammalian cell lines with an average IC₅₀ of 16 μM^[1]. Roscovitine decreases the level of CDK5 and p35 with upregulation of E-cadherin, but downregulation of Vimentin and Collagen IV. Moreover, Roscovitine inhibits the ability of high glucose cultured NRK52E cells to migrate and invade^[2]. In Vivo: Compare with normal controls, Roscovitine downregulates phosphorylated ERK1/2 and PPARγ with concomitant increase in E-cadherin, but decrease in Vimentin and Collagen IV. Correspondingly, Roscovitine decreases renal tubulointerstitial fibrosis of diabetic rats. Roscovitine is effective in decreasing tubulointerstitial fibrosis via the ERK1/2/PPARγ pathway in diabetic rats^[2]. Roscovitine (16.5 mg/kg) significantly reduces the rate of tumor growth and increases survival of treated mice. Strikingly, Roscovitine treatment leads to complete tumor disappearance in one mouse (25%); moreover, no tumor regrowth in this mouse is found 5 months after completion of the treatment. Mouse weights do not differ significantly between mice treated with Roscovitine and control mice, and behavioral differences between the two groups are also negligible. These results suggest that Roscovitine can be used effectively as a selective tumor growth inhibitor in HPV+ head and neck cancer^[3].

References on 186692-46-6 :

Insert title here

Products are for research use only. Not for human use. We do not sell to patients. Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China
TEL: 86-21-58998590 FAX: 86-21-53700326, 86-21-58998590 E-mail： sales@chemexpress.cn